MESO'un PB Oranı emsallerine kıyasla nasıldır?

MESO, Price-To-Book değerine göre iyi bir değerdir. Eş ortalamaya (2.5x) kıyasla oran (3.1x).

MESO'nin PB Oranı, US Biotechs Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

MESO Price-To-Book Oranı ( 2.5 x) baz alındığında, US Biotechs sektör ortalamasına ( 1.8 x) kıyasla pahalıdır.

MESO'nin PB Oranı, Adil PB Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PB Oranıdır.

Değerleme analizi için MESO 'in Price-To-Book Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında MESO 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

MESO ( $10.82 ) [[adil değer]] tahminimizin altında işlem görüyor ( $167.14 )

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Fiyat tahminini göstermek için yeterli veri yok.

Mesoblast (Nasdaq:MESO) - Hisse Senedi Fiyatı, Haberler ve Analizler

MESO Stoklara Genel Bakış

Mesoblast Limited Avustralya, Amerika Birleşik Devletleri, Singapur ve İsviçre'de rejeneratif tıp ürünlerinin geliştirilmesiyle ilgilenmektedir. Daha fazla detay

MESO temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 93.5% daha düşük bir oranda işlem görüyor

Kazançların yılda 61.47% oranında artması öngörülüyor

Risk Analizi

Hissedarlar geçen yıl sulandırıldı

Son 3 ayda dalgalı hisse senedi fiyatı

Mesoblast Limited Rakipler

Gracell Biotechnologies

NasdaqGS:GRCL

US$990.8m

Arcus Biosciences

NYSE:RCUS

US$1.3b

CareDx

NasdaqGM:CDNA

US$1.2b

Prothena

NasdaqGS:PRTA

US$756.0m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Mesoblast
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$10.82
52 Haftanın En Yüksek Seviyesi	AU$12.18
52 Haftanın En Düşük Seviyesi	AU$1.61
Beta	2.34
11 Aylık Değişim	12.12%
3 Aylık Değişim	68.27%
1 Yıllık Değişim	303.73%
33 Yıllık Değişim	-15.20%
5 Yıllık Değişim	-14.80%
Halka arzdan bu yana değişim	32.73%

Son Haberler & Güncellemeler

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Sep 30

Mesoblast: Rolling The Dice On Cellular Medicines

Jul 22

Recent updates

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Apr 30

Mesoblast issues FQ2 operational and financial update

Jan 29

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Jan 11

Mesoblast: The Future Looks Bleak

Dec 24

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Dec 15

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Dec 02

Mesoblast EPS beats by $0.22, misses on revenue

Nov 19

Hissedar Getirileri

	MESO	US Biotechs	US Pazar
7D	-7.6%	-7.5%	-1.2%
1Y	303.7%	14.1%	30.4%

Getiri vs. Endüstri: MESO geçen yıl % 14.1 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: MESO geçen yıl % 30.4 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is MESO's price volatile compared to industry and market?
MESO volatility
MESO Average Weekly Movement	11.1%
Biotechs Industry Average Movement	9.7%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: MESO hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: MESO 'nin haftalık oynaklığı son bir yılda 17% dan 11% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2004	73	Silviu Itescu	www.mesoblast.com

Mesoblast Limited Avustralya, Amerika Birleşik Devletleri, Singapur ve İsviçre'de rejeneratif tıp ürünlerinin geliştirilmesiyle ilgilenmektedir. Tescilli rejeneratif tıp teknolojisi platformu, mezenkimal soy hücreleri olarak bilinen özelleşmiş hücrelere dayanmaktadır. Şirket, steroid refrakter akut graft versus host hastalığı ve biyolojik refrakter inflamatuar bağırsak hastalığı ve Crohn hastalığı dahil olmak üzere sistemik inflamatuar hastalıkların tedavisi için Faz III klinik çalışmalarında olan Remestemcel-L'yi ve kronik kalp yetmezliği ve dejeneratif disk hastalığına bağlı kronik bel ağrısını tedavi etmek için Faz III klinik çalışmalarında olan Remestemcel-L'yi sunmaktadır.

Mesoblast Limited Temel Bilgiler Özeti

Mesoblast'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MESO temel i̇stati̇sti̇kler
Piyasa değeri	US$1.20b
Kazançlar(TTM)	-US$87.96m
Gelir(TTM)	US$5.90m

202.7x

P/S Oranı

-13.6x

F/K Oranı

MESO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MESO gelir tablosu (TTM)
Gelir	US$5.90m
Gelir Maliyeti	US$41.07m
Brüt Kâr	-US$35.17m
Diğer Giderler	US$52.79m
Kazançlar	-US$87.96m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.077
Brüt Marj	-595.87%
Net Kâr Marjı	-1,490.27%
Borç/Özkaynak Oranı	23.8%

MESO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MESO Stoklara Genel Bakış

Ödüller

Risk Analizi

Mesoblast Limited Rakipler

NasdaqGS:GRCL

US$990.8m

NYSE:RCUS

US$1.3b

NasdaqGM:CDNA

US$1.2b

NasdaqGS:PRTA

US$756.0m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast: Rolling The Dice On Cellular Medicines

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Mesoblast Limited: Back From The Dead

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Mesoblast GAAP EPS of -$0.14, revenue of $10.21M

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Mesoblast Limited Provides Litigation Update

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDS

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Mesoblast Limited Announces Positive Outcomes of First Children Treated with Remestemcel-L for Multisystem Inflammatory Syndrome (MIS-C) and Heart Failure Post-Covid-19 Published in Pediatrics

Mesoblast Limited Announces Results from the Phase 3 Randomized Controlled Trial of Its Allogeneic Mesenchymal Precursor Cell Therapy

Mesoblast issues FQ2 operational and financial update

Mesoblast Limited Presents Heart Failure Phase 3 Trial Results At Investor Healthcare Conference

Mesoblast Limited Announces Additional Results from the Landmark Dream-Hf Randomized Controlled Phase 3 Trial in 537 Treated Patients with Chronic Heart Failure with Reduced Left Ventricular Ejection Fraction (HFrEF) Who Received Rexlemestrocel-L (REVASCOR) or Control Sham

Mesoblast's rexlemestrocel-l reduces heart attacks, strokes

Mesoblast: The Future Looks Bleak

Mesoblast Limited Announces Update on Covid-19 ARDS Trial

Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure

Mesoblast fails to meet primary endpoint of reduction in recurrent non-fatal heart failure events

Mesoblast Limited Announces United States Food and Drug Administration Granted Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to Covid-19 Infection

Mesoblast Limited Announces FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19

Mesoblast cell therapy Fast Track'd for COVID-19-related acute respiratory distress syndrome; shares up 14%

Mesoblast Limited announced that it expects to receive $25 million in funding from Novartis AG

Mesoblast Limited Enters into an Exclusive Worldwide License and Collaboration Agreement with Novartis for the Development, Manufacture and Commercialization of Remestemcel-L